DDX60

Summary

DDX60 (DExD/H-box helicase 60, HGNC:25942) is a protein-coding gene on chromosome 4q32.3, encoding Probable ATP-dependent RNA helicase DDX60 (Q8IY21). Positively regulates RIGI- and IFIH1/MDA5-dependent type I interferon and interferon inducible gene expression in response to viral infection.

DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases which are implicated in a number of cellular procsses involving RNA binding and alteration of RNA secondary structure. This gene encodes a DEXD/H box RNA helicase that functions as an antiviral factor and promotes RIG-I-like receptor-mediated signaling.

Source: NCBI Gene 55601 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 243 total — 1 pathogenic
• MANE Select transcript: NM_017631

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25942
Approved symbol	DDX60
Name	DExD/H-box helicase 60
Location	4q32.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20035
Ensembl gene	ENSG00000137628
Ensembl biotype	protein_coding
OMIM	613974
Entrez	55601

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 8 protein_coding, 4 retained_intron, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000393743, ENST00000505393, ENST00000507815, ENST00000511317, ENST00000513997, ENST00000514995, ENST00000679510, ENST00000679744, ENST00000680771, ENST00000680917, ENST00000680998, ENST00000681832, ENST00000902212, ENST00000902213, ENST00000902214, ENST00000953223

RefSeq mRNA: 2 — MANE Select: NM_017631 NM_001410861, NM_017631

CCDS: CCDS34097, CCDS93666

Canonical transcript exons

ENST00000393743 — 38 exons

Exon	Start	End
ENSE00000929945	168267841	168267983
ENSE00000929946	168267582	168267691
ENSE00000929952	168237286	168237427
ENSE00000929953	168236252	168236373
ENSE00000929954	168225529	168225676
ENSE00000929956	168224243	168224385
ENSE00000929959	168221730	168221881
ENSE00001015918	168220655	168220717
ENSE00001015920	168216294	168217032
ENSE00001295396	168252509	168252656
ENSE00001312372	168250954	168251106
ENSE00001364824	168318622	168318752
ENSE00002433522	168293787	168293945
ENSE00002439367	168246418	168246618
ENSE00002450014	168310998	168311067
ENSE00002454099	168237691	168237795
ENSE00002461456	168285393	168285498
ENSE00002463487	168275345	168275503
ENSE00002474531	168288174	168288315
ENSE00002475049	168273934	168274083
ENSE00002486503	168284820	168284935
ENSE00002494666	168308006	168308195
ENSE00002495984	168302300	168302416
ENSE00002500208	168273279	168273398
ENSE00002501435	168306379	168306720
ENSE00002504722	168280335	168280590
ENSE00002505513	168268854	168268969
ENSE00002506699	168283446	168283606
ENSE00002510689	168272043	168272138
ENSE00002512946	168248188	168248292
ENSE00002526419	168291748	168291906
ENSE00002534059	168276015	168276181
ENSE00002534288	168287048	168287203
ENSE00002727583	168311256	168311365
ENSE00003470579	168260865	168260989
ENSE00003578553	168255711	168255869
ENSE00003644473	168262683	168262787
ENSE00003675994	168262000	168262128

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 94.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.3894 / max 1810.1230, expressed in 1465 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
54756	6.8942	699
54757	4.3611	1307
54755	0.1341	61

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	94.81	gold quality
colonic mucosa	UBERON:0000317	94.36	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.14	gold quality
decidua	UBERON:0002450	93.62	gold quality
calcaneal tendon	UBERON:0003701	92.87	gold quality
palpebral conjunctiva	UBERON:0001812	90.92	gold quality
rectum	UBERON:0001052	90.26	gold quality
parietal pleura	UBERON:0002400	89.78	gold quality
mucosa of paranasal sinus	UBERON:0005030	89.77	gold quality
epithelium of nasopharynx	UBERON:0001951	89.40	gold quality
pleura	UBERON:0000977	89.15	gold quality
germinal epithelium of ovary	UBERON:0001304	88.87	gold quality
visceral pleura	UBERON:0002401	88.72	gold quality
bronchial epithelial cell	CL:0002328	88.07	gold quality
duodenum	UBERON:0002114	87.46	gold quality
mucosa of transverse colon	UBERON:0004991	86.96	gold quality
leukocyte	CL:0000738	86.66	gold quality
monocyte	CL:0000576	86.50	gold quality
mononuclear cell	CL:0000842	86.49	gold quality
placenta	UBERON:0001987	85.68	gold quality
transverse colon	UBERON:0001157	85.57	gold quality
epithelium of bronchus	UBERON:0002031	85.48	gold quality
upper leg skin	UBERON:0004262	85.17	gold quality
ventricular zone	UBERON:0003053	85.12	gold quality
seminal vesicle	UBERON:0000998	84.81	gold quality
gall bladder	UBERON:0002110	84.68	gold quality
bronchus	UBERON:0002185	84.62	gold quality
skin of hip	UBERON:0001554	84.60	gold quality
large intestine	UBERON:0000059	84.56	gold quality
granulocyte	CL:0000094	84.49	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7052	yes	1315.77
E-ANND-3	yes	5.42

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting DDX60, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-1287-3P	99.63	66.93	492
HSA-MIR-567	99.63	68.57	1219
HSA-MIR-3128	99.50	67.85	1258
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-7849-3P	99.47	68.17	1224
HSA-MIR-297	99.40	69.58	1418
HSA-MIR-1244	99.33	68.38	832
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-942-3P	98.81	69.04	876
HSA-MIR-606	98.72	67.34	960
HSA-MIR-496	98.66	69.80	931
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-6509-3P	98.32	67.33	1343
HSA-MIR-4704-3P	98.28	69.33	1300

Literature-anchored findings (GeneRIF, showing 8)

• DDX60 is a novel antiviral helicase promoting RIG-I-like receptor-mediated signaling. (PMID:21791617)
• Results define DDX60 as a sentinel for cytoplasmic antiviral response, which is counteracted by virus-mediated EGF receptor activation. (PMID:25981042)
• DDX60 is a novel and unfavorable biomarker for tumorigenesis and prognosis of oral squamous cell carcinoma in a subsite-specific manner (PMID:27835882)
• Glomerular endothelial expression of type I IFN-stimulated gene, DExD/H-Box helicase 60 via toll-like receptor 3 signaling: possible involvement in the pathogenesis of lupus nephritis. (PMID:35392757)
• Integrative Bioinformatics Analysis Identifies DDX60 as a Potential Biomarker for Systemic Lupus Erythematosus. (PMID:36655136)
• Possible involvement of DExD/H box helicase 60 in synovial inflammation of rheumatoid arthritis: role of toll-like receptor 3 signaling. (PMID:38236450)
• DDX60 Promotes Migration and Invasion of Head and Neck Squamous Cell Carcinoma Cell through the NF-kappaB/IFI27 Signaling Pathway. (PMID:38287816)
• Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry. (PMID:39365875)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ddx60	ENSMUSG00000037921
rattus_norvegicus	LOC134478918	ENSRNOG00000056947
rattus_norvegicus	Ddx60	ENSRNOG00000059097

Paralogs (8): MTREX (ENSG00000039123), POLQ (ENSG00000051341), ASCC3 (ENSG00000112249), SNRNP200 (ENSG00000144028), HFM1 (ENSG00000162669), HELQ (ENSG00000163312), DDX60L (ENSG00000181381), SKIC2 (ENSG00000204351)

Protein

Protein identifiers

Probable ATP-dependent RNA helicase DDX60 — Q8IY21 (reviewed: Q8IY21)

Alternative names: DEAD box protein 60

All UniProt accessions (8): Q8IY21, A0A3G9HN97, A0A7P0T8Y0, A0A7P0T9W8, A0A7P0TAZ7, D6R944, H0Y8Z7, H0Y9B2

UniProt curated annotations — full annotation on UniProt →

Function. Positively regulates RIGI- and IFIH1/MDA5-dependent type I interferon and interferon inducible gene expression in response to viral infection. Binds ssRNA, dsRNA and dsDNA and can promote the binding of RIGI to dsRNA. Exhibits antiviral activity against hepatitis C virus and vesicular stomatitis virus (VSV).

Subunit / interactions. Interacts with EXOSC1, EXOSC4, RIGI, IFIH1/MDA5 and DHX58/LGP2.

Subcellular location. Cytoplasm.

Tissue specificity. Brain, lymph node, prostate, stomach, thyroid, tongue, trachea, uterus, skeletal muscle, spleen, kidney, liver and small intestine.

Induction. By interferon (IFN). Up-regulated during vesicular stomatitis virus (VSV), or poliovirus (PV) infection.

Similarity. Belongs to the helicase family.

RefSeq proteins (2): NP_001397790, NP_060101* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001650	Helicase_C-like	Domain
IPR011545	DEAD/DEAH_box_helicase_dom	Domain
IPR014001	Helicase_ATP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR052431	SKI2_subfamily_helicases	Family
IPR055124	PIN-like_DDX60	Domain
IPR059032	WHD_DDX60	Domain

Pfam: PF00270, PF00271, PF23002, PF26076, PF26167

Catalyzed reactions (Rhea), 1 shown:

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (11 total): sequence conflict 4, domain 2, sequence variant 2, chain 1, short sequence motif 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IY21-F1	82.54	0.32

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 785–792

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 331 (showing top): WALLACE_PROSTATE_CANCER_RACE_UP, chr4q32, MODULE_255, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, MODULE_317, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, IRF7_01, GOBP_REGULATION_OF_IMMUNE_RESPONSE, ONKEN_UVEAL_MELANOMA_UP, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, WANG_LMO4_TARGETS_DN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_REGULATION_OF_RESPONSE_TO_STRESS

GO Biological Process (6): response to virus (GO:0009615), innate immune response (GO:0045087), defense response to virus (GO:0051607), positive regulation of MDA-5 signaling pathway (GO:1900245), positive regulation of RIG-I signaling pathway (GO:1900246), immune system process (GO:0002376)

GO Molecular Function (12): double-stranded DNA binding (GO:0003690), RNA helicase activity (GO:0003724), double-stranded RNA binding (GO:0003725), single-stranded RNA binding (GO:0003727), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), nucleotide binding (GO:0000166), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), helicase activity (GO:0004386), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), intermediate filament cytoskeleton (GO:0045111)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of pattern recognition receptor signaling pathway	2
positive regulation of intracellular signal transduction	2
RNA binding	2
ATP-dependent activity	2
binding	2
cellular anatomical structure	2
response to other organism	1
immune response	1
defense response to symbiont	1
defense response	1
response to virus	1
positive regulation of immune effector process	1
MDA-5 signaling pathway	1
regulation of MDA-5 signaling pathway	1
RIG-I signaling pathway	1
regulation of RIG-I signaling pathway	1
biological_process	1
DNA binding	1
helicase activity	1
ATP-dependent activity, acting on RNA	1
catalytic activity, acting on RNA	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
nucleic acid binding	1
nucleic acid conformation isomerase activity	1
catalytic activity, acting on a nucleic acid	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1
cytoskeleton	1

Protein interactions and networks

STRING

1931 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DDX60	RIGI	O95786	963
DDX60	IFIH1	Q9BYX4	940
DDX60	DHX58	Q96C10	792
DDX60	IFIT1	P09914	753
DDX60	OASL	Q15646	745
DDX60	ISG15	P05161	727
DDX60	IFIT3	O14879	718
DDX60	IFIT2	P09913	718
DDX60	OAS1	P00973	704
DDX60	DHX36	Q9H2U1	692
DDX60	DHX29	Q7Z478	674
DDX60	HERC5	Q9UII4	664
DDX60	IFI44	Q8TCB0	622
DDX60	DDX1	Q92499	618
DDX60	MX1	P20591	614

IntAct

18 interactions, top by confidence:

A	B	Type	Score
EIF3E	DDX60	psi-mi:“MI:0915”(physical association)	0.500
rep	DDX60	psi-mi:“MI:0915”(physical association)	0.400
DDX60	NFYC	psi-mi:“MI:0915”(physical association)	0.400
SDC1	ILVBL	psi-mi:“MI:0915”(physical association)	0.400
M6pr	DPM1	psi-mi:“MI:0914”(association)	0.350
Smchd1	SETD1A	psi-mi:“MI:0914”(association)	0.350
Smchd1	SRRM1	psi-mi:“MI:0914”(association)	0.350
CDK2AP1	MTA3	psi-mi:“MI:0914”(association)	0.350
FYCO1	RFT1	psi-mi:“MI:0914”(association)	0.350
SORT1	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
CD74		psi-mi:“MI:0914”(association)	0.350
DDX60	G6PD	psi-mi:“MI:0914”(association)	0.350
TP53	SUPT5H	psi-mi:“MI:0914”(association)	0.350
TRAF3	POLA1	psi-mi:“MI:0914”(association)	0.350
DDX60	USP19	psi-mi:“MI:0914”(association)	0.350
ATF3	C11orf98	psi-mi:“MI:0914”(association)	0.350
tktA	DDX60	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (98): DDX60 (Affinity Capture-MS), DDX60 (Affinity Capture-MS), DDX60 (Affinity Capture-MS), DDX60 (Affinity Capture-MS), DDX60 (Affinity Capture-MS), DDX60 (Affinity Capture-MS), DDX60 (Affinity Capture-MS), DDX60 (Synthetic Lethality), DDX60 (Affinity Capture-MS), AIFM1 (Affinity Capture-MS), AKAP8L (Affinity Capture-MS), ASCC2 (Affinity Capture-MS), ASCC3 (Affinity Capture-MS), BAG2 (Affinity Capture-MS), BAG5 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GW35, A6QNM3, B0R034, B1ANS9, B9EK06, D2KC46, D3ZY60, F1MS15, F1P065, F1REV3, O00522, O15091, O75747, P10911, P58069, Q008S8, Q14449, Q14D04, Q15283, Q32NR9, Q45GW3, Q4R366, Q4R6T7, Q5H9U9, Q5K651, Q5PQS3, Q5XGX5, Q5XIZ9, Q5ZLD2, Q60862, Q63713, Q69Z37, Q6DCF6, Q6S5J6, Q6TNJ1, Q75PQ8, Q80W71, Q86VD1, Q86YR7, Q8C5W4

Diamond homologs: A0FLQ6, O08307, O34996, O51498, O52225, O75417, P19821, P30313, P35207, P46835, P52027, P52028, P56105, P74933, P80194, Q09475, Q54XN7, Q5H9U9, Q8CGS6, Q8IY21, Q9P7T8, Q9RAA9, Q9S1G2, Q9V0A9, A2PYH4, A2RUV5, A7IB61, B6DMK2, D0KN27, D3Z4R1, E1BNG3, E7F8F4, E9PZJ8, F0NDL2, F1LNJ2, F1LPQ2, F1NTD6, O48534, O60072, O75643

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

243 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	175
Likely benign	24
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1047894	GRCh37/hg19 4q32.1-34.1(chr4:157771352-172496278)	Pathogenic

SpliceAI

5323 predictions. Top by Δscore:

Variant	Effect	Δscore
4:168220714:CATC:C	acceptor_gain	1.0000
4:168220716:TC:T	acceptor_gain	1.0000
4:168220716:TCC:T	acceptor_loss	1.0000
4:168220717:CC:C	acceptor_gain	1.0000
4:168220717:CCT:C	acceptor_loss	1.0000
4:168220718:C:CC	acceptor_gain	1.0000
4:168220718:CTAAA:C	acceptor_loss	1.0000
4:168220719:T:C	acceptor_loss	1.0000
4:168221725:CATA:C	donor_loss	1.0000
4:168221726:ATACC:A	donor_loss	1.0000
4:168221727:TA:T	donor_loss	1.0000
4:168221728:A:AC	donor_gain	1.0000
4:168221728:ACCT:A	donor_loss	1.0000
4:168221729:C:A	donor_loss	1.0000
4:168221729:C:CC	donor_gain	1.0000
4:168221877:GTAAC:G	acceptor_gain	1.0000
4:168221878:TAAC:T	acceptor_gain	1.0000
4:168221882:C:CC	acceptor_gain	1.0000
4:168224236:CACT:C	donor_loss	1.0000
4:168224237:ACTT:A	donor_loss	1.0000
4:168224238:CTTA:C	donor_loss	1.0000
4:168224239:TTACA:T	donor_loss	1.0000
4:168224240:T:TG	donor_loss	1.0000
4:168224241:A:AC	donor_gain	1.0000
4:168224241:A:T	donor_loss	1.0000
4:168224242:C:CA	donor_loss	1.0000
4:168224242:C:CC	donor_gain	1.0000
4:168224242:CA:C	donor_gain	1.0000
4:168224242:CATG:C	donor_gain	1.0000
4:168224242:CATGG:C	donor_gain	1.0000

AlphaMissense

11373 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:168275350:A:G	W767R	0.999
4:168275350:A:T	W767R	0.999
4:168246609:G:T	R1325S	0.998
4:168248262:C:G	G1297R	0.998
4:168273947:A:T	V814D	0.998
4:168274016:T:A	K791I	0.998
4:168274034:G:T	A785D	0.998
4:168246605:G:T	A1326D	0.997
4:168246608:C:G	R1325P	0.997
4:168248283:C:G	A1290P	0.997
4:168272053:A:T	I887K	0.997
4:168274017:T:G	K791Q	0.997
4:168275348:C:A	W767C	0.997
4:168275348:C:G	W767C	0.997
4:168248261:C:T	G1297D	0.996
4:168272134:A:G	L860P	0.996
4:168273394:A:G	L820P	0.996
4:168273951:A:C	Y813D	0.996
4:168273980:A:G	L803P	0.996
4:168274015:T:A	K791N	0.996
4:168274015:T:G	K791N	0.996
4:168274019:C:T	G790D	0.996
4:168274076:A:G	L771P	0.996
4:168272053:A:C	I887R	0.995
4:168272128:G:T	T862K	0.995
4:168273370:A:T	V828D	0.995
4:168273394:A:T	L820H	0.995
4:168274082:C:G	R769P	0.995
4:168275345:C:A	Q768H	0.995
4:168275345:C:G	Q768H	0.995

dbSNP variants (sampled 300 via entrez): RS1000035072 (4:168258005 A>C,G), RS1000036310 (4:168284483 C>A,T), RS1000048325 (4:168242252 G>C), RS1000103846 (4:168216135 T>G), RS1000169172 (4:168218770 C>T), RS1000188282 (4:168319553 A>G), RS1000221881 (4:168309632 G>A), RS1000250182 (4:168289149 CGTT>C), RS10002662 (4:168290853 G>C), RS1000273587 (4:168233870 A>AT), RS1000283261 (4:168319262 A>G), RS10002944 (4:168291177 G>A,T), RS1000325793 (4:168253900 T>C), RS1000336727 (4:168247731 T>C), RS10003512 (4:168285748 G>A,C)

Disease associations

OMIM: gene MIM:613974 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

71 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, affects methylation, decreases expression	4
Valproic Acid	decreases expression	4
Estradiol	affects cotreatment, increases expression, decreases expression	3
Nickel	decreases expression, increases expression	3
potassium chromate(VI)	affects cotreatment, decreases expression	2
epigallocatechin gallate	affects cotreatment, decreases expression	2
(+)-JQ1 compound	decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Benzo(a)pyrene	decreases expression, increases methylation	2
Silicon Dioxide	increases expression	2
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Cadmium Chloride	decreases expression	2
aristolochic acid I	decreases expression	1
sotorasib	affects cotreatment, increases expression	1
TL8-506	affects cotreatment, increases expression	1
2,4,6-tribromophenol	decreases expression	1
methylmercuric chloride	decreases expression	1
alpha phellandrene	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
bisphenol A	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression, affects localization	1
decabromobiphenyl ether	decreases expression	1
trichostatin A	decreases expression	1
arsenite	affects binding, decreases reaction	1
tetrabromobisphenol A	decreases expression	1
perfluorooctanoic acid	decreases expression	1
tobacco tar	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1F1	Abcam A-549 DDX60 KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer